Moderna advancing CMV vaccine, adds coronavirus vaccine to pipeline

Moderna (NASDAQ:MRNA) announces that enrollment in its Phase 2 clinical trial evaluating its mRNA vaccine (mRNA-1647) against cytomegalovirus (CMV) is proceeding ahead of schedule with preliminary data now expected in Q3.

It has added three new pipeline programs: mRNA-1189 (Epstein-Barr vaccine), mRNA-1345 (RSV vaccine) and mRNA-1273 (coronavirus vaccine).

It also announces that the first patient has been enrolled in a Phase 1/2 study of mRNA-3704 in patients with a rare inborn error of metabolism called isolated methylmalonic acidemia due to MUT deficiency, an Orphan Drug-, Fast Track- and Rare Pediatric Disease-tagged indication in the U.S.

Shares down 6% premarket in reaction to its planned equity offering.

https://seekingalpha.com/news/3540483-moderna-advancing-cmv-vaccine-adds-coronavirus-vaccine-to-pipeline